

제 25 장

폐경주변기 여성의 피임

1. Baldwin K, Jensen T. Contraception during the perimenopause. *Maturitas* 2013; 76: 235 – 242.
2. Bhatena K, Guillebaud J. Contraception for the older woman: an update. *Climacteric* 2006; 9: 264–76.
3. Cavazos-Rehg A, Krauss J, Spitznagel L, et al. Maternal age and risk of labor and delivery complications. *Maternal Child Health J* 2015; 19: 1202–1211.
4. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance. First prescription of combined oral contraception. *J Fam Plann Reprod Health Care* 2003; 29: 209–23.
5. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance. The copper intrauterine device as long-term contraception. *J Fam Plann Reprod Health Care* 2004; 30: 29–42.
6. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance. Contraception for women aged over 40 years. *J Fam Plann Reprod health Care* 2005; 31: 51–64.
7. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance. The use of contraception outside the terms of the product licence. *J Fam Plann Reprod Health Care* 2005; 31: 225–42.
8. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance. Emergency contraception. *J Fam Plann Reprod Health Care* 2006; 32: 121–8.
9. Finer B, Zolna M. Declines in unintended pregnancy in the United States, 2008–2011. *N Engl J Med* 2016; 374: 843–852.
10. Klein J, Sauer V. Assessing fertility in women of advanced reproductive age. *Am J Obstet Gynecol* 2001; 185: 758 – 770.
11. Menken J, Trussell J, Larsen U. Age and infertility. *Science* 1986; 223: 1389–1394.
12. Miller A, Allen H, Kaunitz M, et al. Contraception for midlife women: a review. *Menopause* 2018; 25: 817.
13. National Institute for Health and Care Excellence (NICE). Menopause: Full-Guideline. 2015. <https://www.nice.org.uk/guidance/ng23/evidence/full-guideline-559549261>.

14. Nelson M, Telfer E, Anderson A. The ageing ovary and uterus: new biological insights. *Hum Reprod Update* 2013; 19: 67 – 83.
15. Reproductive Endocrinology and Infertility Committee, Family Physicians Advisory Committee, Maternal – Fetal Medicine Committee, et al. Advanced reproductive age and fertility. *J Obstet Gynaecol Can* 2011; 33: 1165 – 7115.
16. Brooker C, Guillebaud J. Unanswered questions in contraceptive management: what do the experts do? *J Fam Plann Reprod Health Care* 2004; 30: 229–35.
17. Connell EB. Rational use of oral contraceptives in the perimenopausal woman. *J Reprod Med* 1993; 38: S1036–40.
18. Creinin MD. Laboratory criteria for menopause in women using oral contra-ceptives. *Fertility and Sterility [Research Support, Non-US Gov't]* 1996; 66(July(1)): 101–4.
19. Castracane VD, Gimpel T, Goldzieher JW. When is it safe to switchfrom oral contra-ceptives to hormonal replacement therapy? *Contraception*1995; 52(December (6)): 371–6.
20. FSRH Clinical Effectiveness Unit. FSRH Guidance: Contraception for Women Aged over 40 Years. Available at: <https://www.fsrh.org/standards-and-guidance/documents/fsrhguidance-contraception-for-women-aged-over-40-years-2017/>. Accessed October, 2017.
21. Gebbie A. Contraception in the perimenopause. *Br Menopause J* 2003; 9: 123–8.
22. Guideline FFPEHC(January 2005) contraception for women aged over 40 years. *journal of Family planning and Reproductive Health care* ≥ [Guideline Practice Guideline Review]2005; 31(January (1)): 101–4
23. Kaeser L. Reconsidering the age limits on pill use. *Fam Plann Perspect* 1989; 21: 273–4.
24. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. *Contraception* 2007; 75: S70 – S75.
25. Westhoff C. Contraception at age 35 years and older. *Clinical Obstet Gynecol.* 1998; 41: 951–7.
26. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. *Contraception* 1992; 46: 575–84.
27. Castracane VD, Gimpel T, Goldzieher JW. When is it safe to switch from oral contra-ceptives to hormonal replacement therapy? *Contraception* 1995; 52: 371–6.
28. Corson SL. Oral contraceptives for the prevention of osteoporosis. *J Reprod Med* 1993; 38:S1015–20.
29. Contraception for women aged over 40 years (CEU guidance). *J Fam Plann Reprod Health Care*2005; 31: 51–63.

30. Drife JO. The benefits and risks of oral contraceptives today. Parthenon Publishing Group Press;1996. p.37.
31. Fathalla MF, Rosenfield A, Indriso C. Family planning ; The FIGO. Manual of human reproduction; 1990. p.38.
32. Fedele L, Portuese A, Bianchi S, Dorta M, Raffaelli R. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. *Fertil Steril* 1997; 68: 426-9.
33. Fong YF, Singh K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. *Contraception* 1999; 60: 51-3.
34. Friedman AJ, Thomas PP. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? *Obstet Gynecol* 1995; 85: 631-5.
35. Gray RH. Biological and social interactions in determination of late fertility. *J Biosoc Sci* 1979;Suppl 6: 97-115.
36. John Guillebaud. *Contraception today*. 3rd ed. London: Martin Dunitz Press; 1997. p.34.
37. Kailas NA, Sifakis S and Koumantakis E. Contraception during perimenopause. *Eur J Contracept Reprod Health Care* 2005; 10: 19-25.
38. Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a d-norgestrelreleasing intrauterine device. *Fertil Steril* 1978; 29: 397-401.
39. Odland V. Contraceptive efficacy and side effects of levonorgestrel-releasing intrauterine system. *Gynaecology Forum* 1998; 3: 14.
40. Oloto E, Mascarenhas L. Subdermal contraceptive implants. *Br J Fam Plann* 2000; 26: 171-4.
41. Porter C, Rees MCP. Bleeding problems and progestogen-only contraception. *J Fam Plann Reprod Health Care* 2002; 28: 178-81.
42. Rybo G. Treatment of menorrhagia using intrauterine administration of levonorgestrel. *Gynaecology Forum*. 1998; 3: 20.
43. Schneider HPG. Hazards in perimenopausal contraception. *European J Contraception and Reproductive Health Care*. 1997; 2: 95-100.
44. Schwartz D, Mayaux MJ. Female fecundity as a function of age results of artificial insemination in 2193 nulliparous women with azoospermic husbands. *Federation CE-COS.. N Eng J Med* 1982; 30: 404-6.
45. Shaaban MM. The perimenopause and contraception. *Maturitas* 1996; 23: 181-92.
46. Suvanto-Luukkonen E, Kauppila A. A levonorgestrel-releasing intrauterine system in menopausal hormone replacement therapy : five-year experience. *Fertil Steril*

- 1999; 72: 161-3.
47. Thorneycroft IH. Oral contraceptives during the menopausal transition. *Menopause management* 1998; 7: 23.
 48. Vercellini P, Aimi G, Panazza S, de Giorgi O, Pesole A, Crosignani PG : A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis : a pilot study. *Fertil Steril* 1999; 72: 505-8.
 49. Von Hertzen H, Piaggio G, Ding J, et al. for the World Health Organization Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. *Lancet* 2002; 360: 1803-10.
 50. Webb AM. Emergency contraception. *Br Med J* 2003; 326: 775-76.
 51. World Health Organization (WHO). *Medical Eligibility Criteria for Contraceptive Use*, 5th ed. Geneva: WHO; 2004. <http://www.who.int/reproductive-health/publications/mec/mec.pdf>.